1,873
Views
15
CrossRef citations to date
0
Altmetric
Editorials

What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?

&

References

  • de Leon J, Arranz MJ, Ruaño G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008;28(4):599–617.
  • Shader RI. Some thoughts about medical caring. J Clin Psychopharmacol. 2015;35(2):115–116.
  • Katsanis SH, Javitt G, Hudson K. Public health. A case study of personalized medicine. Science. 2008;320(5872):53–54.
  • Henderson D, Ogilvie LA, Hoyle N, et al. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014;9(9):1104–1114.
  • de Leon J. Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatr. 2014;26(6):327–333.
  • de Leon J. Is psychiatry only neurology? Or only abnormal psychology? Déjà vu after 100 years. Acta Neuropsychiatr. 2015;27(2):69–81.
  • de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59(2):81–89.
  • Crettol S, de Leon J, Hiemke C, et al. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther. 2014;95(3):254–257.
  • Senn S, Rolfe K, Julious SA. Investigating variability in patient response to treatment – a case study from a replicate cross-over study. Stat Methods Med Res. 2011;20(6):657–666.
  • de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32(2):153–164.
  • Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm. 2015;122(1):5–28.
  • de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology. 2009;34(1):159–172.
  • Cappell K, Arndt M, Carey J. Drugs get smart. Business Week 2005 Sep 5; 76–85.
  • de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther. 2006;10(3):135–151.
  • Jones PM. FDA regulation of LDTs-an update. MLO Med Lab Obs. 2015;47(9):18–19.
  • Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20(2):246–251.
  • de Leon J. Translating pharmacogenetics to clinical practice: do cytochrome P450 2D6 ultrarapid metabolizers need higher atomoxetine doses? J Am Acad Child Adolesc Psychiatry. 2015;54(7):532–534.
  • Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
  • Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364(12):1126–1133.
  • Fibiger HC. Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophr Bull. 2012;38(4):649–650.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.